Trials / Recruiting
RecruitingNCT04512833
CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis
CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Beijing 302 Hospital · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Cyberknife stereotactic body radiation therapy | A total dose of 45-54 Gy in 5-10 fractions was given according to the location of lesions for small HCC patients with decompensated cirrhosis. |
Timeline
- Start date
- 2020-08-12
- Primary completion
- 2023-08-30
- Completion
- 2026-08-30
- First posted
- 2020-08-14
- Last updated
- 2023-06-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04512833. Inclusion in this directory is not an endorsement.